Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nephros (NEPH) Research & Development (2016 - 2025)

Nephros has reported Research & Development over the past 16 years, most recently at $395000.0 for Q4 2025.

  • Quarterly results put Research & Development at $395000.0 for Q4 2025, up 56.75% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 47.79% YoY), and the annual figure for FY2025 was $1.3 million, up 47.79%.
  • Research & Development for Q4 2025 was $395000.0 at Nephros, up from $338000.0 in the prior quarter.
  • Over the last five years, Research & Development for NEPH hit a ceiling of $556000.0 in Q1 2021 and a floor of $188000.0 in Q3 2024.
  • Median Research & Development over the past 5 years was $284000.0 (2022), compared with a mean of $307000.0.
  • Biggest five-year swings in Research & Development: crashed 47.4% in 2021 and later skyrocketed 79.79% in 2025.
  • Nephros' Research & Development stood at $328000.0 in 2021, then increased by 9.45% to $359000.0 in 2022, then plummeted by 42.06% to $208000.0 in 2023, then grew by 21.15% to $252000.0 in 2024, then soared by 56.75% to $395000.0 in 2025.
  • The last three reported values for Research & Development were $395000.0 (Q4 2025), $338000.0 (Q3 2025), and $311000.0 (Q2 2025) per Business Quant data.